These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25275651)

  • 1. Structural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display.
    Nagata T; Shirakawa K; Kobayashi N; Shiheido H; Tabata N; Sakuma-Yonemura Y; Horisawa K; Katahira M; Doi N; Yanagawa H
    PLoS One; 2014; 9(10):e109163. PubMed ID: 25275651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
    Shiheido H; Takashima H; Doi N; Yanagawa H
    PLoS One; 2011 Mar; 6(3):e17898. PubMed ID: 21423613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Does the Recently Discovered Peptide MIP Exhibit Much Higher Binding Affinity than an Anticancer Protein p53 for an Oncoprotein MDM2?
    Yamada T; Hayashi T; Hikiri S; Kobayashi N; Yanagawa H; Ikeguchi M; Katahira M; Nagata T; Kinoshita M
    J Chem Inf Model; 2019 Aug; 59(8):3533-3544. PubMed ID: 31282659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
    Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
    J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
    Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
    Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
    Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
    J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a novel MDM2 binding peptide based on the p53 family.
    Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
    Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction.
    Rasafar N; Barzegar A; Mehdizadeh Aghdam E
    Sci Rep; 2020 Jul; 10(1):11449. PubMed ID: 32651397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
    Niu RJ; Zheng QC; Zhang JL; Zhang HX
    J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
    Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
    Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
    Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
    J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.